within Pharmacolibrary.Drugs.ATC.J;

model J05AX10
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.000255,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.047,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010666666666666666,
    Tlag           = 15.0,            
    Vdp             = 0.034,
    k12             = 23.9,
    k21             = 23.9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AX10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Maribavir is an orally administered antiviral medication used for the treatment of cytomegalovirus (CMV) infection and disease in transplant recipients. It is a benzimidazole riboside and acts by inhibiting the CMV UL97 protein kinase, disrupting viral DNA synthesis and encapsidation. Maribavir is approved for clinical use by regulatory agencies such as the US FDA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after single and multiple-dose oral administration.</p><h4>References</h4><ol><li><p>Swan, SK, et al., &amp; Villano, SA (2007). Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. <i>Journal of clinical pharmacology</i> 47(2) 209–217. DOI:<a href=\"https://doi.org/10.1177/0091270006296765\">10.1177/0091270006296765</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17244772/\">https://pubmed.ncbi.nlm.nih.gov/17244772</a></p></li><li><p>Song, IH, et al., &amp; Sun, K (2024). Population pharmacokinetics and exposure-response relationships of maribavir in transplant recipients with cytomegalovirus infection. <i>Journal of pharmacokinetics and pharmacodynamics</i> 51(6) 887–904. DOI:<a href=\"https://doi.org/10.1007/s10928-024-09939-2\">10.1007/s10928-024-09939-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39333337/\">https://pubmed.ncbi.nlm.nih.gov/39333337</a></p></li><li><p>Sun, K, et al., &amp; Song, IH (2024). Maribavir: Mechanism of action, clinical, and translational science. <i>Clinical and translational science</i> 17(1) e13696–None. DOI:<a href=\"https://doi.org/10.1111/cts.13696\">10.1111/cts.13696</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38071422/\">https://pubmed.ncbi.nlm.nih.gov/38071422</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AX10;
